1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Financial - Conglomerates
Immage Biotherapeutics Corp.

Immage Biotherapeutics Corp.

IMMG
Immage Biotherapeutics Corp.US flagOther OTC
0.00
USD
- -
- -
15,174.00Market Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
-0.01
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
1,365
561
- -
145
147
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
-2
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
May'16
Aug'16
Nov'17
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
147
147
152
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
May'16
Aug'16
Nov'17
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
551.12%
Free Cash Flow
- -
- -
1,125.28%
Net Income, GAAP
- -
- -
1,066.67%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Zhi Cong Mou
Full Time Employees
3
Sector
Financial Services
Industry
Financial - Conglomerates
Address
10411 Motor City Drive Bethesda United States of America
IPO Date
Dec 2, 2022
Website
immagebio.com
Similar Companies
X3 Acquisition Corp. Ltd. Unit (XCBEU)
Iron Dome Acquisition I Corp. Units (IDACU)
JDC Group AG (JDC.DE)
Twenty One Capital Inc (XXI)
AlphaTime Acquisition Corp Right (ATMCR)
Praetorian Acquisition Corp. Wt (PTORW)
Business
Immage Biotherapeutics Corp. Immage Biotherapeutics Corp. (IMMG) is a biotechnology company focused on developing cancer immunotherapies, including vaccines, oncolytic viruses, adjuvants, and adoptive T-cell technologies targeting melanoma-associated antigen-A (MAGE-A); it employs bioinformatics and outsourced laboratory resources for rapid candidate development, with plans to advance fusion/hybrid antigen vaccines effective against MAGE-A isomers 1-11 that are HLA-free, as well as immunotherapy candidates from its intellectual property library using viral vector constructs for human clinical trials, particularly for breast and prostate cancers. Founded in 2012 by Anton Dormer and Mahesh Narayanan and headquartered at 10411 Motor City Drive, Suite 750, Bethesda, Maryland, the company operates primarily in the United States with a small team of four employees led by CEO Zhi Cong Mou, CTO Anton Dormer, COO Mahesh Narayanan, and CFO Elton Norman. In recent developments, Immage Biotherapeutics initiated a repeat toxicology study for its lead candidate IMT-001 in May 2025, though the board voted to terminate operations as of August 31, 2025, following evaluation of available options, marking a significant wind-down after previously changing its name from Epicure Charcoal, Inc. in June 2015.